Molsidomine


Full Prescribing Info
Dosage/Direction for Use

Oral
Angina pectoris
Adult: 1-4 mg 2-4 times daily.

Oral

Heart failure
Adult: 1-4 mg 2-4 times daily.

Oral

Post myocardial infarction
Adult: 1-4 mg 2-4 times daily.

Intravenous

Angina pectoris
Adult: 2-4 mg as a single dose; 2 mg may be repeated at intervals of at least 2 hr if necessary. Max: 40 mg daily. Infusions may be employed at a rate of up to 3 mg/hr.
Max Dosage: 40 mg daily.

Intravenous

Heart failure
Adult: 2-4 mg as a single dose; 2 mg may be repeated at intervals of at least 2 hr if necessary. Max: 40 mg daily. Infusions may be employed at a rate of up to 3 mg/hr.
Max Dosage: 40 mg daily.

Intravenous

Post myocardial infarction
Adult: 2-4 mg as a single dose; 2 mg may be repeated at intervals of at least 2 hr if necessary. Max: 40 mg daily. Infusions may be employed at a rate of up to 3 mg/hr.
Max Dosage: 40 mg daily.
Contraindications
Shock. Pregnancy and lactation.
Special Precautions
Hepatic insufficiency.
Adverse Reactions
Arterial hypotension, orthostatic hypotension, pruritus, rash, anorexia, nausea, headache, vertigo.
Action
Molsidomine is a nitrovasodilator.
Absorption: Rapidly absorbed from the GI tract. Bioavailability (oral): 44-59%. Peak plasma concentrations in 1-2 hr.
Distribution: Protein-binding of parent compound: 3-11%.
Metabolism: Hepatic; metabolised to lindidomine and other morpholine derivatives.
Excretion: Via urine. Half-life: 1-2 hr; prolonged in patients with liver cirrhosis.
CIMS Class
ATC Classification
C01DX12 - molsidomine ; Belongs to the class of other vasodilators used in cardiac diseases.
Disclaimer: This information is independently developed by CIMS based on molsidomine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in